PHE885 is an autologous T cell genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR) and manufactured with a new process that is being tested in patients with multiple myeloma.
SparkCures ID | 376 |
---|---|
Developed By | Novartis |
Generic Name | PHE885 |
Treatment Classifications | |
Treatment Targets |
View all active clinical trials around the US.
There are no resources, links or videos to display for this treatment.